Podcasts about valvular heart disease

Commentary by Dr. Jian'an Wang.

Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826251399637

Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826251399512

Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826251374642

Defining the Prevalence of Valvular Heart Disease in Older Americans: The PREVUE-VALVE Study

Focus Issue on Valvular Heart Disease and Dyslipidaemias

In this episode of The Nurse Practitioner Podcast, Julia Rogers, DNP, APRN, CNS, FNP-BC, FAANP and Christina Cantey, DNP, FNP-C, AACC, CCK discuss the transcatheter revolution in the treatment of valvular heart disease.

Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826251370475

Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826251330128

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with Dr. Marc Pelletier, division chief of cardiac surgery for the Department of Surgery at Yale School of Medicine, about patient blood management. Chapters 00:00 Intro 01:45 EACTS 2025 07:19 JANS 1, HVD Management Guidelines 16:26 JANS 2, Low-Risk AVR Evidence 19:21 JANS 3, Warden Procedure Selection 20:36 JANS 4, Primary Repair of CAT 21:48 JANS 5, NEWTON-CABG Cardiolink-5 23:20 Video 1, Acute Aortic Syndrome 24:54 Video 2, Redo TVR Under Bypass 27:13 Video 3, Giant Tension Bulla 28:47 Dr. Pelletier Interview 34:25 Outro They delve into the Society of Thoracic Surgeons (STS) guidelines on patient blood management, along with key tips. They also explore preoperative optimization, provide an example, and discuss cell savers and reducing dead space during surgery. Additionally, they touch on postoperative transfusion and the importance of performing meticulous surgery.  Joel also highlights recent JANS articles on the 2025 ESC/EACTS guidelines for the management of valvular heart disease, low-risk aortic valve replacement at the crossroads of evidence, ideal age and weight for the Warden procedure in patients with partial anomalous pulmonary venous return, a systematic meta-analysis of short- and long-term outcomes of the primary repair of common arterial trunk, and an international, randomized, double-blind, placebo-controlled trial on the effect of Evolocumab on saphenous vein graft patency after coronary artery bypass surgery.  In addition, Joel explores the surgical treatment of acute aortic syndrome, a redo tricuspid valve replacement technique under right heart bypass for a previously repaired tricuspid valve, and thoracoscopic resection of a giant tension bulla. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease: Developed by the Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)   2.) Low-Risk Aortic Valve Replacement at the Crossroads of Evidence  3.) Is There an Ideal Age or Weight for the Warden Procedure in Patients With Partial Anomalous Pulmonary Venous Return?  4.) Primary Repair of Common Arterial Trunk: A Systematic Meta-Analysis of Short- and Long-Term Outcomes  5.) Effect of Evolocumab on Saphenous Vein Graft Patency After Coronary Artery Bypass Surgery (NEWTON-CABG CardioLink-5): An International, Randomized, Double-Blind, Placebo-Controlled Trial  CTSNet Content Mentioned  1.) Surgical Treatment of Acute Aortic Syndrome   2.) Redo Tricuspid Valve Replacement Technique Under Right Heart Bypass for a Previously Repaired Tricuspid Valve   3.) Thoracoscopic Resection of a Giant Tension Bulla   Other Items Mentioned  1.) STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management  2.) Transcatheter vs Surgical Aortic Valve Replacement in Lower-Risk Patients: An Updated Meta-Analysis of Randomized Controlled Trials  3.) Perfecting TAVR Removal | Skills Sharpening With Vince Gaudiani  4.) Career Center   5.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

Join us as Dr. John Winterton, cardiologist at Willis-Knighton Pierremont Cardiology, explains valvular heart disease, from symptoms and risks to diagnosis and treatment. A clear, expert look at how to keep your heart valves, and your health, in check.

This episode covers: Cardiology This Week: A concise summary of recent studies Strategic decisions in valvular heart disease Optimising drug therapy in chronic coronary syndromes Mythbusters: Does wearing a white coat make you smarter? Host: Susanna Price Guests: John-Paul Carpenter, Fabien Praz, Robert Storey Want to watch that episode? Go to: https://esc365.escardio.org/event/2092 Want to watch that extended interview on Optimising drug therapy in chronic coronary syndromes ? Go to: https://esc365.escardio.org/event/2092?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel, Fabien Praz and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Robert Storey has declared to have potential conflicts of interest to report: research grants and personal fees from AstraZeneca and Cytosorbents, and personal fees from Abbott, Afortiori Development/Thrombolytic Science, Boehringer Ingelheim/Lilly, Bristol Myers Squibb/Johnson & Johnson, Chiesi, Idorsia/Viatris, Novo Nordisk, PhaseBio and Tabuk. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Focus Issue on Thrombosis and Antithrombotic Treatment and Valvular Heart Disease

Focus Issue on Valvular Heart Disease and Epidemiology, Prevention, and Health Care Policies

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

KYW Newsradio's Rasa Kaye and Deborah Heart and Lung Center's Interventional Cardiologist, Dr. Muhammad Raza continue their discussion on diagnosing and treating valvular heart disease and the exciting future in the heart valve research space.

Focus Issue on Genetics and Valvular Heart Disease

KYW Newsradio's Rasa Kaye and Deborah Heart and Lung Center's Interventional Cardiologist, Dr. Muhammad Raza discuss diagnosing and treating valvular heart disease and the exciting future in the heart valve research space.

Focus Issue on Valvular Heart Disease

Focus Issue on Valvular Heart Disease, Heart Failure and Cardiomyopathies

Focus Issue on Heart Failure and Valvular Heart Disease

With Kwan-Leung CHAN & Lawrence Lau, University of Ottawa Heart institute - Canada. Link to editorial Link to paper

Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research that was presented at the 2024 European Society of Cardiology annual meeting. Visit NEJM.org to read the latest research.

Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research that was presented at the 2024 European Society of Cardiology annual meeting. Visit NEJM.org to read the latest research.

Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research that was presented at the 2024 European Society of Cardiology annual meeting. Visit NEJM.org to read the latest research.

Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research that was presented at the 2024 European Society of Cardiology annual meeting. Visit NEJM.org to read the latest research.

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

Focus Issue on Heart Failure, Valvular Heart Disease, and Arrhythmias

Focus Issue on Valvular Heart Disease, Diabetes, Metabolic Disorders, and Hypertension

In this episode, Tim Madeira, cardiothoracic DNP,  provides an overview of the primary heart valve diseases. He expertly guides us through the complex physiological processes underlying conditions like stenosis and valve regurgitation arising from congenital abnormalities, calcifications, infective endocarditis, and trauma. In addition, Tim outlines the latest evidence-based standards in surgical, percutaneous and medical interventions that nurses find themselves managing in the hospital.Check out Nicole Kupchik's exam reviews and practice questions at nicolekupchikconsulting.com. Use the promo code UPMYGAME20 to get 20% off all products.Do you need help with your resume, interviewing, or need career coaching? Check out Sarah at New Thing Nurse:Get 15% off of her resume and cover letter templates using the promo code UPMYGAMENursing students and new grad career services Experienced RN career servicesNP career servicesSee the show notes at upmynursinggame.com.

Host: Darryl S. Chutka, M.D. [@chutkaMD] Guest: Rekha Mankad, M.D. Mitral valve disorders are extremely common, one of the most common is mitral valve prolapse. The majority of these patients live their life without symptoms, but some go on to develop significant mitral regurgitation or less likely, mitral stenosis. How can we recognize mitral valve disease and what's recommended to confirm a diagnosis? How should these patients be followed? Do they need a lifetime of cardiac imaging? When is a cardiologist needed to help manage these patients? In this podcast, we'll discuss these questions and more with cardiologist Rekha Mankad, M.D., a cardiologist from the Mayo Clinic. Connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Host: Darryl S. Chutka, M.D. [@chutkaMD] Guest: Rekha Mankad, M.D. It's estimated that between 2% and 3% of the population has some form of valvular heart disease and this increases with age. Most of these patients are initially cared for by primary care providers. Most valvular disease deaths are due to disease of the aortic valve and it's important to recognize these patients early in order to assess for progression and the need for surgical intervention. What are the presenting symptoms of aortic valve disease? What's the best way to manage and follow these patients and when should a cardiologist and cardiac surgeon become involved in the care of the patient? In this podcast, we'll discuss these questions and more with cardiologist Rekha Mankad, M.D., from the Mayo Clinic. Connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Commentary by Dr. Valentin Fuster

Focus Issue on Valvular Heart Disease

Dr. Pierre Elias sits down with Catherine Price to talk about how utilizing technologies like artificial intelligence and machine learning can help diagnose patients even before symptoms develop, and support doctors by freeing them up to focus on providing personalized care to their patients. They discuss navigating bias in both artificial intelligence and clinical care, and how new technology will improve the future of medicine. For more information visit nyp.org/Advances

This episode covers valvular heart disease and murmurs.Written notes can be found at https://zerotofinals.com/medicine/cardiology/valvularheartdisease/ or in the cardiology section of the 2nd edition of the Zero to Finals medicine book.The audio in the episode was expertly edited by Harry Watchman.

With Daniela Tomasoni and Marianna Adamo, University of Brescia, Brescia - Italy. In November's HFA Cardio Talk, Dr. Daniela Tomasoni interviews Dr.Marianna Adamo on valvular heart disease in heart failure. The podcast starts with an epidemiological overview and then addresses the main pathophysiological mechanisms of valvular heart disease in patients with heart failure. It also discusses current recommendations regarding the treatment of mitral regurgitation. In conclusion, dr. Adamo will guide us through the new available percutaneous devices for the treatment of tricuspid regurgitation.

Commentary by Dr. Valentin Fuster

Focus Issue on Valvular Heart Disease

Why Quantitative Measures Matter in Valvular Heart Disease Guest: Jeremy J. Thaden, M.D. (@JeremyThaden) Host: Kyle W. Klarich, M.D. (@KyleWKlarich) Joining us today to discuss Why Quantitative Measures Matter in Valvular Heart Disease is Jeremy Thaden, M.D., assistant professor of cardiovascular medicine and vice chair for the division of cardiac ultrasound at Mayo Clinic in Rochester, Minnesota. Specific topics discussed: How do you use valve quantification in echo and what are specific examples of quantitation in valvular heart disease? What is the benefit of quantifying valvular lesions? Where do you see echo quantitation going in the future? Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV. NEW Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.    

DCS 1401: Valvular heart disease

Commentary by Dr. Valentin Fuster

Do you have a reliable roadmap for optimizing care during a crisis? On MedAxiom HeartTalk, host Melanie Lawson speaks with guests Elizabeth Perpetua, DNP, ACNP-BC, FACC, Kimberly Guibone, DNP, ACNP-BC, FACC, Martina Kelly Speight, MSN, FNP-BC, and Joan Michaels, RN, MSN, CPHQ. They share insights from their PEARLS paper – a blueprint for structural heart programs to optimize care and improve outcomes while facing profound obstacles.Guest Bios:Elizabeth Perpetua, DNP, ACNP-BC, FACC: Founder of Empath Health Services and faculty at University of Washington in Seattle – Dr. Perpetua led the efforts and development of the PEARLS paper and the first published study describing the Structural Heart Coordinator role and Coordination in the U.S. She is a Doctor of Nursing Practice with 15 years of experience in structural heart program development and research. She was the Director of the structural heart programs at Swedish Medical Center and University of Washington before starting her work in consulting and education. Dr. Perpetua has trained thousands of nurses, physicians, and administrators in structural heart disease.Kimberly Guibone, DNP, ACNP-BC, FACC: Structural Heart Clinical Program Manager at Beth Israel Deaconess Medical Center in Boston. Dr. Guibone brings extensive experience as a Doctor of Nursing Practice and the first valve coordinator of her structural heart program. She has contributed to multiple research papers helping to define the role of the valve center coordinator.Martina Kelly Speight, MSN, FNP-BC: Board-certified Nurse Practitioner in the Structural Heart Program at Stanford Health Care in California. Martina established her role on the Stanford multidisciplinary heart team in 2008 where she coordinated research efforts and greatly contributed to program development. In her role as Nurse Practitioner, Martina Speight has become a clinical expert in the care and management of patients undergoing treatment for Valvular Heart Disease. She is passionate about leading efforts that improve program outcomes, efficiencies, and patient experiences. Martina has contributed to multiple publications and speaks nationally about Heart Valve Disease and Structural Heart Program development.Joan Michaels, RN, MSN, CPHQ: Director of Cardiac Registries for the American College of Cardiology in D.C. Joan brings more than 30 years of experience in cardiology as a registered nurse and expertise overseeing the STS/ACC TVT Registry.

In this episode we discuss cardiogenic shock due to valvular heart disease. Join Dr. Pranoti Hiremath (Interventional cardiology fellow, Johns Hopkins), Dr. Karan Desai (CN Critical Care Series Co-Chair, Cardiology fellow, University of Maryland), Dr. Yoav Karpenshif (CN Critical Care Series Co-Chair, Chief cardiology fellow, University of Pennsylvania), and Amit Goyal (CardioNerds Co-Founder) as they interview Dr. Paul Cremer (Associate Director of the Cardiac Intensive Care Unit and Associate Director of the Cardiovascular Fellowship at the Cleveland Clinic) in this broad overview of valvular shock. We discuss the nuances in diagnosis, differing presentations and how physical exam, multi-modality imaging, and invasive hemodynamics can inform management. Audio editing by Dr. Gurleen Kaur (Director of the CardioNerds Internship and CardioNerds Academy Fellow). The CardioNerds Cardiac Critical Care Series is a multi-institutional collaboration made possible by contributions of stellar fellow leads and expert faculty from several programs, led by series co-chairs, Dr. Mark Belkin, Dr. Eunice Dugan, Dr. Karan Desai, and Dr. Yoav Karpenshif. Pearls • Notes • References • Guest Profiles • Production Team CardioNerds Cardiac Critical Care PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls and Quotes - Cardiogenic Shock and Valvular Heart Disease Shock due to valve disease is the result of a structural abnormality that may be temporized with medical therapy and circulatory support devices. However, it is ultimately best treated with a structural solution in the form of either percutaneous valvular therapies or cardiac surgery.When treating a patient with cardiogenic shock with normal or hyperdynamic ventricular function, we should keep a high index of suspicion for valvular disease. The cardiac output may be reduced due to a stenotic lesion “blocking” forward flow or regurgitant lesion causing backward flow.Acute mitral and aortic regurgitation will typically not manifest as a loud murmur on physical exam. The combination of hypotension and rapid flow of regurgitant blood on an “unprepared” cardiac chamber results in rapid equalization of chamber pressures, shortening the intensity and duration of the murmur. On transthoracic echocardiogram, for instance with acute MR, color Doppler may not show a large turbulent jet, and thus the MR may be underestimated or not appreciated at all.Echocardiography is critical to understand the etiology and severity of valvular shock, and invasive hemodynamics are often needed to guide medical and mechanical interventions.In multi-valve disease with severe aortic stenosis and functional mitral regurgitation, we typically treat the aortic stenosis first, since the mitral regurgitation may improve from the reduction in afterload associated with treating aortic stenosis. Show notes - Cardiogenic Shock and Valvular Heart Disease 1. Shock due to valve disease arises due to a structural problem that may be temporized with medical therapy and circulatory support devices, but is ultimately best treated with a structural solution in the form of either percutaneous valvular therapies or cardiac surgery. Stabilizing therapies for acute mitral regurgitation include afterload reduction with vasodilators, diuresis as needed to reduce pulmonary edema, and mechanical circulatory support including intra-aortic balloon pumps.Therapies for acute aortic regurgitation are typically more limited and include vasopressors such as epinephrine.  Bradycardia should be avoided with agents such as dobutamine or temporary pacing to reduce time in diastole. Temporary mechanical circulatory support options are limited in the setting of acute AR, though case reports of techniques such as LAVA ECMO (left atrial venoarterial extracorpeal membr...

The eighth panel of DCS 1400: Valvular Heart disease

The eighth panel of DCS 1400: Valvular Heart disease

#017  In this episode we will discuss commonly encountered cardiac valve disorders including:Mitral RegurgitationAortic StenosisMitral StenosisAortic RegurgitationRemember to head over to my website and subscribe while you are there to receive a Basic Rhythm Interpretation Cheat Sheet!  www.kayhoppepresents.com Join me on Facebook for the 'CCRN Question of the Day Challenge' @kayhoppepresentsStay tuned for the Online CCRN Review Course coming in September 2021I hope to see you in future episodes!Have a blessed day!Kaykay@kayhoppepresents.com

In this episode, two game-changer trials about transcatheter edge to edge repair will be reviewed, we hope you enjoy this epsidoeyou can also download the slides via this link:http://ecardiocast.com/wp-content/uploads/2021/05/Secondary-MR-TEER.pdf

In this episode, you will find the latest pathophysiology, etiologies, classification, and management of secondary mitral regurgitation, enjoy the next 20 minutes being with usyou can also download the slides via this link:http://ecardiocast.com/wp-content/uploads/2021/05/secondary-MR-1.pdf